Want to see CH:GALD full AI Analyst Report?
GALD Stock Chart & Stats
CHF173.65
-CHF0.05(-0.03%)
At close: 4:00 PM EDT
CHF173.65
-CHF0.05(-0.03%)
Day’s Range― - ―
52-Week RangeCHF127.60 - CHF188.25
Previous CloseN/A
Volume352.30K
Average Volume (3M)337.59K
Market Cap
CHF41.27B
Enterprise ValueCHF44.67K
Total Cash (Recent Filing)CHF841.26M
Total Debt (Recent Filing)CHF2.70B
Price to Earnings (P/E)53.2
Beta0.80
Next Earnings
Mar 11, 2027EPS Estimate
2.03Next Dividend Ex-DateN/A
Dividend Yield0.2%
Share Statistics
EPS (TTM)4.09
Shares Outstanding237,897,630
10 Day Avg. Volume210,266
30 Day Avg. Volume337,589
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)5.94
Price to Sales (P/S)9.24
P/FCF Ratio46.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF208.83Price Target Upside20.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)4.74
Revenue Forecast (FY)CHF6.37B
Bulls Say, Bears Say
Bulls Say
High Gross Margins & Rising EBIT MarginSustained gross margins near 67–70% and an EBIT margin up to ~16.4% indicate durable pricing power and operating leverage in dermatology franchises. This margin base supports reinvestment in R&D and marketing, cushioning profitability if revenue growth moderates.
Material Free Cash Flow GenerationStrong 2025 operating and free cash flow demonstrates improved cash conversion, enabling debt paydown, capex funding, and strategic investments. High cash quality (FCF ~87% of net income) supports long-term financial flexibility and lowers reliance on external financing.
Marked Deleveraging And Equity RebuildSubstantial reduction in leverage over several years materially improves financial resilience and strategic optionality. Lower debt ratios reduce interest burden, improve credit flexibility for M&A or R&D investment, and strengthen the firm's ability to absorb shocks.
Bears Say
Top-line InconsistencyA revenue decline in 2025 despite profit improvement signals fragility in demand or product mix. Persistent top-line volatility complicates planning for capacity, R&D and commercial investments, and could strain margin maintenance if sales rebound fails to be sustained.
Historical Cash-flow VolatilityPast negative FCF and uneven operating cash flow through 2022–2024 show the business can experience sharp cash swings. Such volatility raises risk that recent FCF gains may not persist through industry cycles or product transitions, affecting long-term funding plans.
Large Absolute Debt BurdenEven with improved debt-to-equity, a nominal debt load near $2.75B requires continued strong cash generation to service and refinance. That size of debt constrains aggressive capital allocation choices and increases refinancing risk if revenue or cash flow weakens.
Galderma Group AG News
GALD FAQ
What was Galderma Group AG’s price range in the past 12 months?
Galderma Group AG lowest stock price was CHF127.60 and its highest was CHF188.25 in the past 12 months.
What is Galderma Group AG’s market cap?
Galderma Group AG’s market cap is CHF41.27B.
When is Galderma Group AG’s upcoming earnings report date?
Galderma Group AG’s upcoming earnings report date is Mar 11, 2027 which is in 216 days.
How were Galderma Group AG’s earnings last quarter?
Galderma Group AG released its earnings results on Jul 23, 2026. The company reported CHF1.034 earnings per share for the quarter, missing the consensus estimate of CHF1.441 by -CHF0.407.
Is Galderma Group AG overvalued?
According to Wall Street analysts Galderma Group AG’s price is currently Undervalued.
Does Galderma Group AG pay dividends?
Galderma Group AG pays a Annually dividend of CHF0.35 which represents an annual dividend yield of 0.2%. See more information on Galderma Group AG dividends here
What is Galderma Group AG’s EPS estimate?
Galderma Group AG’s EPS estimate is 2.03.
How many shares outstanding does Galderma Group AG have?
Galderma Group AG has 237,897,630 shares outstanding.
What happened to Galderma Group AG’s price movement after its last earnings report?
Galderma Group AG reported an EPS of CHF1.034 in its last earnings report, missing expectations of CHF1.441. Following the earnings report the stock price went down -2.729%.
Which hedge fund is a major shareholder of Galderma Group AG?
Currently, no hedge funds are holding shares in CH:GALD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Galderma Group AG
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
GALD Stock 12 Month Forecast
Average Price Target
CHF208.83
▲(20.26% Upside)